Synta to raise $35M to further cancer compounds including HSP inhibitor
This article was originally published in Scrip
Executive Summary
Synta Pharmaceuticals has announced a registered direct offering of 7.2 million shares to institutional investors and company insiders to advance its R&D, which includes investigational cancer compounds.